{"product_id":"zphc-retatrutide-40mg-kit-uae","title":"ZPHC Retatrutide 40mg Kit | Advanced Triple Agonist Peptide","description":"\u003ch1\u003eZPHC Retatrutide 40mg Kit | Weight Loss \u0026amp; Metabolic Injection Guide\u003c\/h1\u003e\u003cp\u003eZPHC Retatrutide 40mg Kit is associated with retatrutide, an investigational peptide being studied for its activity across three important hormone receptor pathways: GIP, GLP-1, and glucagon. Because of this three-pathway activity, retatrutide is commonly described as a triple hormone receptor agonist or triple agonist.\u003c\/p\u003e\u003cp\u003eRetatrutide is also known by the development code LY3437943. Current research is examining its potential role across several metabolic and cardiometabolic conditions, making retatrutide an important subject of ongoing pharmaceutical research.\u003c\/p\u003e\u003ch2\u003eWhat Is ZPHC Retatrutide 40mg Kit?\u003c\/h2\u003e\u003cp\u003eZPHC Retatrutide 40mg Kit is a product name associated with retatrutide research material. The exact composition, formulation, purity and laboratory specifications of any particular ZPHC product should be confirmed through the manufacturer's current documentation and applicable certificate of analysis.\u003c\/p\u003e\u003cp\u003eRetatrutide itself is being investigated as a single molecule capable of activating three receptor systems:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGIP receptor\u003c\/li\u003e\n\u003cli\u003eGLP-1 receptor\u003c\/li\u003e\n\u003cli\u003eGlucagon receptor\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThis combination distinguishes retatrutide from compounds that act on only one or two of these pathways.\u003c\/p\u003e\u003ch2\u003eRetatrutide as an Advanced Triple Agonist Peptide\u003c\/h2\u003e\u003cp\u003eRetatrutide is described by Eli Lilly as a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist. The molecule is being studied in Phase 3 clinical trials across multiple indications.\u003c\/p\u003e\u003cp\u003eThe three receptor pathways are important to current metabolic research:\u003c\/p\u003e\u003ch3\u003eGIP Receptor\u003c\/h3\u003e\u003cp\u003eGIP, or glucose-dependent insulinotropic polypeptide, is a hormone involved in metabolic signaling. Researchers are studying how activation of the GIP receptor contributes to the overall activity of retatrutide.\u003c\/p\u003e\u003ch3\u003eGLP-1 Receptor\u003c\/h3\u003e\u003cp\u003eGLP-1, or glucagon-like peptide-1, is another important metabolic hormone. GLP-1 receptor signaling is an established area of pharmaceutical research involving glucose regulation and appetite-related pathways.\u003c\/p\u003e\u003ch3\u003eGlucagon Receptor\u003c\/h3\u003e\u003cp\u003eGlucagon is involved in metabolic regulation and energy balance. Retatrutide's ability to activate the glucagon receptor alongside GIP and GLP-1 is one of the features that makes it a distinctive research molecule.\u003c\/p\u003e\u003ch2\u003eWhy Is Retatrutide Called a Triple Agonist?\u003c\/h2\u003e\u003cp\u003eRetatrutide is called a triple agonist because it activates three hormone receptors rather than focusing on only one receptor pathway.\u003c\/p\u003e\u003cp\u003eThe three targets can be summarized as:\u003c\/p\u003e\u003cp\u003eGIP + GLP-1 + Glucagon\u003c\/p\u003e\u003cp\u003eThis terminology is more scientifically appropriate than calling retatrutide “GLP-3.” Lilly notes that GLP-3 is not an official scientific classification for retatrutide.\u003c\/p\u003e\u003ch2\u003eRetatrutide Research\u003c\/h2\u003e\u003cp\u003eRetatrutide is currently being evaluated in a broad clinical development program. Research has included obesity, type 2 diabetes, cardiovascular and renal outcomes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain and metabolic dysfunction-associated steatotic liver disease.\u003c\/p\u003e\u003cp\u003eClinicalTrials.gov currently lists Phase 3 studies involving retatrutide, including research comparing retatrutide with tirzepatide in adults with obesity.\u003c\/p\u003e\u003ch2\u003eZPHC Retatrutide 40mg Kit\u003cimg class=\"_resizableImage_1wqvo_111\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/T8M99pVwlblqnxbMdPcv8LQkCycpO4SP2bYo5xOV.png?v=1788106556\"\u003e and Metabolic Research\u003c\/h2\u003e\u003cp\u003eOne reason retatrutide has attracted significant scientific interest is its multi-receptor mechanism.\u003c\/p\u003e\u003cp\u003eResearchers are investigating whether simultaneous activation of GIP, GLP-1 and glucagon receptors can produce different metabolic effects compared with single- or dual-receptor approaches.\u003c\/p\u003e\u003cp\u003eThis makes Retatrutide research an important area within current metabolic and cardiometabolic pharmaceutical development.\u003c\/p\u003e\u003ch2\u003eZPHC Retatrutide 40mg Kit — Product Considerations\u003c\/h2\u003e\u003cp\u003eWhen evaluating a research product described as ZPHC Retatrutide 40mg Kit, researchers should verify product-specific documentation before making any laboratory or quality claims.\u003c\/p\u003e\u003cp\u003eImportant documentation may include:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eProduct identification\u003c\/li\u003e\n\u003cli\u003eBatch or lot number\u003c\/li\u003e\n\u003cli\u003eCertificate of Analysis (COA)\u003c\/li\u003e\n\u003cli\u003ePurity information\u003c\/li\u003e\n\u003cli\u003eAnalytical testing\u003c\/li\u003e\n\u003cli\u003eStorage requirements\u003c\/li\u003e\n\u003cli\u003eManufacturer documentation\u003c\/li\u003e\n\u003cli\u003eIntended research use\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eProduct-specific specifications should always be taken from the actual manufacturer's documentation rather than assumed from the product name.\u003c\/p\u003e\u003ch2\u003eRetatrutide and Current Clinical Development\u003c\/h2\u003e\u003cp\u003eRetatrutide has progressed into Phase 3 clinical development. In July 2026, Eli Lilly reported positive topline results from additional Phase 3 trials and stated that it planned to submit a Biologics License Application for retatrutide in the first quarter of 2027.\u003c\/p\u003e\u003cp\u003eThese developments demonstrate the growing scientific interest in the molecule, but clinical-trial results do not mean that every product marketed under the retatrutide name is an approved medicine.\u003c\/p\u003e\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\u003ch3\u003eWhat is ZPHC Retatrutide 40mg Kit?\u003c\/h3\u003e\u003cp\u003eZPHC Retatrutide 40mg Kit is a product name associated with retatrutide research material. Product-specific specifications should be verified using the manufacturer's documentation and COA.\u003c\/p\u003e\u003ch3\u003eWhat is retatrutide?\u003c\/h3\u003e\u003cp\u003eRetatrutide, also known as LY3437943, is an investigational molecule being developed by Eli Lilly. It activates GIP, GLP-1 and glucagon receptors.\u003c\/p\u003e\u003ch3\u003eWhy is retatrutide called a triple agonist?\u003c\/h3\u003e\u003cp\u003eIt is called a triple agonist because it activates three receptor pathways: GIP, GLP-1 and glucagon.\u003c\/p\u003e\u003ch3\u003eWhat is LY3437943?\u003c\/h3\u003e\u003cp\u003eLY3437943 is the development code for retatrutide.\u003c\/p\u003e\u003ch3\u003eIs retatrutide approved for public use?\u003c\/h3\u003e\u003cp\u003eAs of August 2026, Lilly describes retatrutide as investigational and not yet available for public use. It remains under clinical development.\u003c\/p\u003e\u003ch3\u003eWhat are the three targets of retatrutide?\u003c\/h3\u003e\u003cp\u003eThe three targets are:\u003c\/p\u003e\u003cp\u003eGIP receptor + GLP-1 receptor + glucagon receptor.\u003c\/p\u003e\u003ch2\u003eConclusion\u003c\/h2\u003e\u003cp\u003eZPHC Retatrutide 40mg Kit targets a highly specific product-related search term while connecting the product topic with the broader field of retatrutide research.\u003c\/p\u003e\u003cp\u003eRetatrutide is particularly notable because it is being investigated as a GIP, GLP-1 and glucagon triple hormone receptor agonist. Ongoing Phase 3 research continues to evaluate its potential applications and safety.\u003c\/p\u003e\u003cp\u003eFor research-related product evaluation, always verify the actual product's documentation, testing information and intended-use statement before making product-specific claims.\u003c\/p\u003e\u003ch2\u003e\u003c\/h2\u003e","brand":"Pharma Testostrone","offers":[{"title":"Default Title","offer_id":44629831942232,"sku":null,"price":1400.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/ZPHC_Retatrutide_40mg_Kit.jpg?v=1788106253","url":"https:\/\/timewell.store\/products\/zphc-retatrutide-40mg-kit-uae","provider":"Timewell","version":"1.0","type":"link"}